Successful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 6, 2004, Pages 772-774

  Braun, Jan Peter ^a,b   Schneider, Martin ^a   Dohmen, Pascal ^a   Döpfmer, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

acute myocarditis; biventricular assist device; dilative cardiomyopathy; levosimendan; low output syndrome

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM SENSITIZER; CEFTRIAXONE; DIGOXIN; DOBUTAMINE; ENALAPRIL; ENOXIMONE; FLUCONAZOLE; FUROSEMIDE; GENTAMICIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; LEVOSIMENDAN; MEROPENEM; METOPROLOL; NITROPRUSSIDE SODIUM; VANCOMYCIN;

ARTICLE; ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CASE REPORT; CHILD; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; FEVER; HEART EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; INTUBATION; LABORATORY TEST; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SIDE EFFECT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VIRUS MYOCARDITIS; WEANING;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CALCIUM; CANDIDIASIS; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; CHILD; CROSS INFECTION; ECHOCARDIOGRAPHY; FEMALE; FLUCONAZOLE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; HYDRAZONES; IMMUNOGLOBULINS; INTUBATION, INTRATRACHEAL; MYOCARDITIS; PYRIDAZINES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 11844304944     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2004.08.020     Document Type: Article

References (12)

1. Stiller B., Dahnert I., Weng Y.G., et al. Children may survive severe myocarditis with prolonged use of biventricular assist devices. Heart. 82:1999;237-240
2. Duncan B.W., Bohn D.J., Atz A.M., et al. Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg. 122:2001;440-448
3. McBride B.F., White C.M. Acute decompensated heart failure A contemporary approach to pharmacotherapeutic management [review]. Pharmacotherapy. 23:2003;997-1020
4. Remme W.J., Swedberg K. European Society of Cardiology Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail. 4:2002;11-22
5. Nield L.E., McCrindle B.W., Bohn D.J., et al. Outcomes for children with cardiomyopathy awaiting transplantation. Cardiol Young. 10:2000;358-366
6. Thackray S., Easthaugh J., Freemantle N., et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure A meta-regression analysis. Eur J Heart Fail. 4:2002;515-529
7. Janssen P.M., Datz N., Zeitz O., et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol. 404:2000;191-199
8. Gruhn N., Nielsen-Kudsk J.E., Theilgaard S., et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol. 31:1998;741-749
9. Hasenfuss G., Pieske B., Kretschmann B., et al. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol. 26:(suppl):1995;S45-51
10. Follath F., Cleland J.G., Just H., et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) A randomised double-blind trial. Lancet. 360:2002;196-202
11. Nijhawan N., Nicolosi A.C., Montgomery M.W., et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 34:1999;219-228
12. Lilleberg J., Nieminen M.S., Akkila J., et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 19:1998;660-668